BJH / JLB | Team of Professors Jianxiang Wang and Shaowei Qiu at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Uncover Novel Mechanisms in t(8;21) AML and Identify Potential Therapeutic Targets

BJH / JLB | Team of Professors Jianxiang Wang and Shaowei Qiu at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Uncover Novel Mechanisms in t(8;21) AML and Identify Potential Therapeutic Targets

2025.08.22
Acute myeloid leukemia, subtype M2b (AML-M2b), was first identified in 1959 by Professor Chongli Yang at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), based on clinical features, bone marrow morphology, and cytology. He termed it “subacute granulocytic leukemia.” In 1973, Rowley and colleagues abroad reported the same leukemia subtype through cytogenetic methods. By the late 1990s, the team led by Professor Jianxiang Wang demonstrated that the chromosomal translocation t(8;21) leads to rearrangement of the AML1 and ETO genes, producing the AML1-ETO (RUNX1::RUNX1T1) fusion gene—the molecular hallmark of AML-M2b. This marker has since been widely applied in differential diagnosis and minimal residual disease (MRD) monitoring.
A Trans-Pacific Meeting of Minds: US–China Collaboration in Urology

A Trans-Pacific Meeting of Minds: US–China Collaboration in Urology

2025.08.15
On July 10–11, 2025, Professor Steven Campbell, Chair of Urology at West Virginia University, visited the Sun Yat-sen University Cancer Center (SYSUCC) for a two-day academic exchange. His visit brought an international, cutting-edge perspective to SYSUCC’s Department of Urology while also showcasing the department’s achievements to peers worldwide.
Blood Science Update | TREML2 Enhances Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via Suppression of the ERK Signaling Pathway

Blood Science Update | TREML2 Enhances Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via Suppression of the ERK Signaling Pathway

2025.08.14
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal expansion of myeloid precursor cells. Cytarabine (Ara-C) remains a cornerstone of induction chemotherapy; however, primary and acquired resistance to Ara-C significantly limits its therapeutic efficacy. Emerging studies have suggested that immune checkpoint and receptor molecules may influence tumor chemosensitivity, yet the role of TREML2, a member of the TREM family, has remained largely unexplored in the AML context. This article, published in Blood Science, investigated TREML2 expression in AML and uncovered its role in modulating responsiveness to Ara-C.
Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

2025.08.14
Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial examining the long-term impact of adding Ara-C during consolidation therapy for children with APL.